The discovery that certain cancer cell lines require IRE1 in a nonenzymatic scaffolding capacity, coupled with the failure of IRE1 kinase and/or RNase inhibitors to block growth in such settings18,19, has created the need for a more comprehensive disruption strategy for IRE1. The gene discussed is ERN1; the disease is cancer.